Liang Y. Ma

No. 167, Wutai Mountain Road
Qingdao, 266003, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).

Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008).

Journal: Scientific reports
Published: April 16, 2026

Reply to the Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma".

Reply to the Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma".

Journal: Liver cancer
Published: April 07, 2026

Reply to "Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma'".

Reply to "Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma'".

Journal: Liver cancer
Published: March 26, 2026

Associations between TT-TG distance and rotational and coronal alignment in recurrent patellar dislocation.

Associations between TT-TG distance and rotational and coronal alignment in recurrent patellar dislocation.

Journal: BMC musculoskeletal disorders
Published: March 01, 2026

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection.

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection.

Journal: Alimentary pharmacology & therapeutics
Published: January 25, 2026

Amygdalin alleviates MAFLD via inhibiting cytoplasmic calcium ion overload-induced liver sinusoidal endothelial cell defenestration.

Amygdalin alleviates MAFLD via inhibiting cytoplasmic calcium ion overload-induced liver sinusoidal endothelial cell defenestration.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: December 21, 2025

Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.

Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.

Journal: Liver cancer
Published: December 03, 2025

Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol.

Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocol.

Journal: iLIVER
Published: November 27, 2025

Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study.

Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study.

Journal: European journal of gastroenterology & hepatology
Published: September 18, 2025

Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Journal: Hepatology communications
Published: August 24, 2025

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Journal: Liver cancer
Published: August 16, 2025

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Journal: Liver cancer
Published: July 18, 2025
Showing 1-12 of 183

Last Updated: 09/26/2026